Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Eli Lilly and Company

LLY
Current price
776.38 USD -40.95 USD (-5.01%)
Last closed 806.06 USD
ISIN US5324571083
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 765 281 435 648 USD
Yield for 12 month +29.41 %
1Y
3Y
5Y
10Y
15Y
LLY
21.11.2021 - 28.11.2021

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Address: Lilly Corporate Center, Indianapolis, IN, United States, 46285

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1 008.48 USD

P/E ratio

86.9536

Dividend Yield

0.67 %

Current Year

+34 124 100 000 USD

Last Year

+28 541 400 000 USD

Current Quarter

+11 439 100 000 USD

Last Quarter

+11 302 800 000 USD

Current Year

+27 548 100 000 USD

Last Year

+21 911 600 000 USD

Current Quarter

+9 268 300 000 USD

Last Quarter

+9 132 600 000 USD

Key Figures LLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 16 566 500 352 USD
Operating Margin TTM 39.77 %
PE Ratio 86.9536
Return On Assets TTM 13.95 %
PEG Ratio 0.7575
Return On Equity TTM 65.32 %
Wall Street Target Price 1 008.48 USD
Revenue TTM 40 863 301 632 USD
Book Value 15.83 USD
Revenue Per Share TTM
Dividend Share 5.03 USD
Quarterly Revenue Growth YOY 20.4 %
Dividend Yield 0.67 %
Gross Profit TTM 21 911 600 000 USD
Earnings per share 9.27 USD
Diluted Eps TTM 9.27 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 68.2 %
Profit Margin 20.48 %

Dividend Analytics LLY

Dividend growth over 5 years

101 %

Continuous growth

9 years

Payout Ratio 5 years average

58 %

Dividend History LLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 5.2
Ex Dividend Date 15.11.2024
Forward Annual Dividend Yield 0.65 %
Last Split Factor 2:1
Payout Ratio 51.13 %
Last Split Date 16.10.1997
Dividend Date 10.09.2024

Stock Valuation LLY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 86.9536
Forward PE 35.5872
Enterprise Value Revenue 19.4014
Price Sales TTM 18.7278
Enterprise Value EBITDA 63.3531
Price Book MRQ 53.7363

Financials LLY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators LLY

For 52 weeks

558.93 USD 972.53 USD
50 Day MA 907.88 USD
Shares Short Prior Month 6 582 632
200 Day MA 827.74 USD
Short Ratio 2.19
Shares Short 5 786 764
Short Percent 0.72 %